Özgür ASLAN, Ayser MIZRAKLI, Gülseren SAMANCI AKTAR, Arzu RAHMANALI ONUR

COVİD-19 Geçiren Hastalarda Antikor Düzeylerinin Değerlendirilmesi

Amaç: Ağır akut solunum sendromu korona virus 2 (SARS-CoV-2) hastalığı (COVID-19) halen büyük bir sorun olarak tüm dünyada etkisini göstermektedir. Halen SARS-CoV-2'ye karşı antikor tepkileri tam olarak anlaşılamamıştır ve serolojik testlerin klinik yararları belirsizdir. Bu çalışmada COVID-19 geçiren hastaların farklı zamanda alınmış numunelerde Roche SARS-CoV-2 antikor testi ile antikor düzeyleri değerlendirildi. Yöntemler: Hastanemize 21 kişinin Mart 2020 – Nisan 2020 tarihleri arasındaki SARS-CoV-2 PCR testi bakılmış ve serum numunesi toplanmış kişilerden, Temmuz 2020 ayında tekrar numune alınmış ve toplam 42 numunede Roche SARS-CoV2 antikor düzeyleri bakılmıştır. Bulgular: Toplam 21 kişinin ilk numunesinin 7’sinde Anti SARS CoV 2 antikorları negatif, 14’ünde Anti SARS CoV 2 antikorları pozitif olarak bulunmuştur. Negatif olan numunelerin hepsinde RT-PCR sonuçları pozitif olarak saptanmıştır. İkinci numunelerin 1’inde Anti SARS CoV 2 antikorları negatif, 20’isnde Anti SARS CoV 2 antikorları pozitif olarak bulunmuştur. Tüm kişilerin ikinci numuneleri ele alındığında, SARS-CoV-2 antikor değerlerinde hiçbir numunede düşüş saptanmamıştır.Sonuç: Çalışmada ikinci numunelerde dahi antikor düzeyi negatif ve kısmen düşük cut off değerlerdeki numuneler bulunmaktadır. Bu çalışma gerek antikor düzeylerinin varlığı ve takibi gerekse plazmaferezlerde donör antikor düzeyinin saptanması açısından önem taşımaktadır.

Evaluation of Antibody Levels in Patients with COVID-19

Objective: Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) disease (COVID-19) is still showing its effect as a major problem all over the world. Currently, antibody responses to SARS-CoV-2 are not fully understood, and the clinical benefits of serological testing are uncertain. In this study, antibody levels of patients with COVID-19 were evaluated with Roche SARS-CoV-2 antibody test in samples taken at different times. Method: SARS-CoV-2 PCR tests of 21 people were examined in our hospital between March 2020 and April 2020, and serum samples were collected again in July 2020 and Roche SARS-CoV-2 antibody levels were measured in a total of 42 samples. Results: Anti SARS CoV 2 antibodies were found to be negative in 7 of the first samples of 21 people and Anti SARS CoV 2 antibodies were found to be positive in 14 of them. RT-PCR results were found to be positive in all of these 7 negative samples. Anti-SARS-CoV-2 antibodies were found to be negative in 1 of the second samples, and Anti-SARS-CoV-2 antibodies were found to be positive in 20 of them. Considering the second samples of all subjects, no decrease was detected in the SARS-CoV-2 antibody values in any sample. Conclusions: In the study, there are samples with negative antibody levels and partially low cut off index values even in the second samples. This study is important in terms of both the presence and follow-up of antibody levels and detection of donor antibody levels in plasmapheresis.

PDF

___

1. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020; 87: 281-6.
2. Şit D, Kayabaşı H. SARS-CoV-2 ile İlişkili Akut Böbrek Hasarı. Dicle Tıp Dergisi. 2020; 47: 498-507.
3. Xiang F, Wang X, He X, et al. Antibody Detection and Dynamic Characteristics in Patients with COVID-19. Clin Infect Dis. 2020: ciaa461.
4. https://covid19.who.int/. WHO Coronavirus Disease (COVID-19) Dashboard 2020
5. Tang Y-W, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. 2020; 58: e00512-20.
6. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine. 2020; 26: 845-8.
7. Liu W, Liu L, Kou G, et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. Journal of clinical microbiology. 2020; 58: e00461-20.
8. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 2020; 20: 565- 74.
9. Roche. Elecsys Anti-SARS-CoV-2 09203079500V Cobas system kit prospectus. In: Roche, editor. 2020.
10. Louie JK, Hacker JK, Mark J, et al. SARS and common viral infections. Emerg Infect Dis. 2004; 10: 1143-6.
11. Woo PC, Lau SK, Wong BH, et al. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. Journal of clinical microbiology. 2004; 42: 2306-9.
12. Wang W, Xu Y, Gao R, , et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020; 323: 1843-4.
13. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious diseases. 2020; 20: 398-400.
14. Duan K, Liu B, Li C, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. 2020: 2020.03.16.20036145.
15. Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci. 2020; 59: 102794.